Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=28 A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
Schizophrenia
Primary: Maximum Concentration of Clozapine in Plasma — 524.62; 551.18 ng/mL
Phase 1 N=25 An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
Herpes Labialis
Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061
Phase 1 N=41 Safety and Tolerability Study of N6022 in Healthy Subjects
Healthy
Primary: Safety and Tolerability of a Single Ascending Doses of Intravenous N6022 in Healthy Volunteers — 1; 4; 1; 0 Adverse Events
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Phase 1 N=75 Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma
Advanced Melanoma
Primary: Maximum Observed Serum Concentration (Cmax) of Ipilimumab Manufactured by Process C Relative to the Cmax of Ipilimumab Manufactured by Process B - Evaluable…
Phase 1 N=24 Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Asthma
Primary: Incidence of Adverse Events — 5; 4; 6; 2 Participants
Phase 1 N=2 Enhancing Participation In the Community by Improving Wheelchair Skills: Phase 2
Older Adult Manual Wheelchair Users
Primary: Change From Baseline in Wheelchair Skills Test (WST) 4.1 Capacity Score — 6.25 units on a scale
Phase 1 N=18 Taste and Palatability of Orfadin Suspension
Hereditary Tyrosinemia, Type I
Primary: The Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years — 4.0 units on a scale
Phase 1 N=25 Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
Healthy · Cystic Fibrosis
Primary: Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study…
Phase 1 N=30 A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants
Healthy Participants
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) of Testosterone — 2120; 2400; 2970; 2880 nanograms* hours per deciliter (ng*h/dL)
Phase 1 N=23 Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
Hypertension, Pulmonary · Pulmonary Disease, Chronic Obstructive
Primary: Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean) — -3.60; -4.83 mmHg
Phase 1 N=13 Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
Non-small Cell Lung Cancer
Primary: To Determind the Maximum Tolerable Dose for Antroquinonol — 600 mg
Phase 1 N=11 Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
HIV INFECTIONS
Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects
Phase 1 N=24 Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg — 86.95; 78.80; 38.90 Hour*ng/mL